New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cheplapharm AG · ISIN: DE000CHP2222 · EQS - Company News (23 News)
Country: Germany · Primary market: Germany · EQS NID: 1872373
03 April 2024 10:10AM

Caroline Jacquin appointed Managing Director of CHEPLAPHARM France SAS


EQS-News: Cheplapharm AG / Key word(s): Personnel
Caroline Jacquin appointed Managing Director of CHEPLAPHARM France SAS

03.04.2024 / 10:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


Greifswald / Levallois-Perret, 03. April 2024


Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024. The previous Managing Director of CHEPLAPHARM France, Isabelle Dalle, is retiring.

Caroline Jacquin, an experienced pharmaceutical manager, is taking over the position of Managing Director of the French subsidiary. Caroline can look back on 25 years of experience in leading positions in different pharmaceutical companies in France, Singapore and Mexico. Most recently, she was Marketing and Sales Director at MSD France, where she was leading the Hospital business unit. The previous Managing Director of CHEPLAPHARM in France, Isabelle Dalle, is taking her well-deserved retirement. She has managed the French subsidiary since its foundation in 2016.
fncls.ssp?fn=download2_file&code_str=c852895ce1cf086d642d62ad90fb8109
Edeltraud Lafer, CEO, thanks Isabelle Dalle (left) for her services and welcomes Caroline Jacquin (right) as the new Managing Director of CHEPLAPHARM France


"I am delighted that we have been able to fill the position of the Managing Director of CHEPLAPHARM France with such a high-profile candidate as Caroline Jacquin. With her expertise in the French pharmaceutical market and her international career, Caroline Jacquin is a perfect fit for us and for ourFrench subsidiary, which is important for the entire group," says Edeltraud Lafer, CEO of CHEPLAPHARM Arzneimittel GmbH. "I would like to expressly thank Isabelle Dalle for the work she has done. She has managed the French subsidiary since its foundation with vision and a pioneering spirit and, together with her team, has developed our subsidiary into a central unit of the CHEPLAPHARM Group."

Caroline Jacquin has been Deputy Managing Director at CHEPLAPHARM France since 1 March 2024 and will take over full responsibility from Isabelle Dalle on 1 April, who will remain available to the company in an advisory capacity until the end of the year.

About CHEPLAPHARM
CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 650 people worldwide.

Please refer to www.cheplapharm.com for additional information.

Press office:
CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ press(at)cheplapharm.com
 


03.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cheplapharm AG
Ziegelhof 24
17489 Greifswald
Germany
Phone: 03834 3914 O
E-mail: info@cheplapharm.com
Internet: www.cheplapharm.com
ISIN: DE000CHP2222
WKN: CHP222
EQS News ID: 1872373

Notierung vorgesehen
 
End of News EQS News Service

1872373  03.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1872373&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.